The DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index, and 1 are not checked yet.
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Open accessAbstract
Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multi-step process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all “maybe” abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A meta-analysis reported 31%–73% of breast cancer survivors are adherent to AET,10”
From Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: Protocol for a pilot fractional factorial trial (2023) · cites this paper as [10]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, non-adherence is common with up to three-quarters of women prescribed adjuvant endocrine therapy (HT) taking < 80% of prescribed therapy and similar proportions discontinuing prematurely [4].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of barriers to medication use have been reported in this setting, including medication side-effects, psychological distress and a lack of social support [4, 15].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Non -adherence to adjuvant endocrine therapy (AET) in women with breast cancer is common and associated with medication side -effects and distress.”
The cited source says what the claim attributes to it.
In the citing paper
“Adherence to adjuvant endocrine therapy is affected by medication side-effects and associated distress.”
The cited source says what the claim attributes to it.
In the citing paper
“However, non-adherence is common with up to three-quarters of women prescribed adjuvant endocrine therapy (HT) taking < 80% of prescribed therapy and similar proportions discontinuing prematurely [4].”
The cited source says what the claim attributes to it.
In the citing paper
“Non-adherence to AET is a major problem among women with breast cancer [4]”
In the citing paper
“Despite these benefits, between 31-73% of survivors discontinue adjuvant hormonal therapy in clinical practice,6 thereby reducing treatment efficacy.7-10”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“However, few interventions have been developed to improve adjuvant hormonal therapy adherence.6”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“Patient variables (e.g., age), social support, patient-provider communication, and healthcare factors (e.g., cost) have been associated with breast cancer survivor adherence to systemic therapies.6, 16-18”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“However, adherence to hormonal therapy is suboptimal.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“While hormonal treatment related side effects such as hot flashes and osteoporosis42 represent one of the main reasons for discontinuation,6 none of the retrieved interventions had an explicit focus on side effects.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“Although studies have shown that adherence is problematic in both older and younger women similarly,6 the reasons for discontinuation or barriers to adherence may be different between the two groups.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Tamoxifen for early breast cancer: an overview of the randomised trials
Abe, O., Bartholomeus, S., & Piccart, M. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,180
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
From Cancer Patient to Cancer Survivor: Lost in Transition
(2005) · PsycEXTRA Dataset · doi:10.1037/e720092007-001 · Cited by 2,364
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Research works printed but not linked: 1
- Salgado BA, Zivian MT (2006) Aromatase inhibitors: side effects reported by 622 women. Breast Cancer Res Treat 100:S1618
Cited by
Sorted by citations
Items 601–700 of 710
Characterization and pharmacogenetics of hepatic phase I exemestane metabolism
Peterson, A. (2017) · ProQuest Demo Repository
Addressing Barriers to Medication Adherence: A Screening Instrument Validation Study
Washburn, D. (2019) · 45th Biennial Convention (16-20 November 2019)
Getting in sync with adherence to endocrine therapy in breast cancer
Manz, C. R. (2019) · Cancer · doi:10.1002/cncr.32434
Wechseljahresbeschwerden – Hormonmangel nach der gynäko-onkologischen Therapie
Almstedt, K., & Hasenburg, A. (2019) · Frauenheilkunde up2date · doi:10.1055/a-0891-3557
Tailoring endocrine therapy in early breast cancer
van Hellemond (2019) · doi:10.26481/dis.20191031ih
Endocrine Treatment of Young Patients with EBC
Pagani, O. (2020) · Springer eBooks · doi:10.1007/978-3-030-24762-1_11
Halilintar, V. D., Nadjib, M., & Andalusia, L. R. (2020) · JMMR (Jurnal Medicoeticolegal dan Manajemen Rumah Sakit) · doi:10.18196/jmmr.92120
Toward the patient-centred development of cancer therapeutics: A focus on nanomedicines
Freeman, M. W. (2018) · TSpace (University of Toronto)
Managing menopausal symptoms in patients with hormone receptor-positive gynecologic cancers
Shabalova, O. V., Yureneva, S. V., Khokhlova, S. V., Gardanova, Z. R., & Ermakova, E. I. (2020) · Journal of Modern Oncology · doi:10.26442/18151434.2020.3.200104
Ma, S. J., Yu, B., Oladeru, O. T., Bartl, A. J., Farrugia, M. K., Fekrmandi, F., & Singh, A. K. (2021) · The Breast Journal · doi:10.1111/tbj.14228
Complexité de l’adhésion à l’endocrinothérapie adjuvante après un cancer du sein
Lambert, L. K., Balneaves, L. G., & Howard, A. F. (2021) · PubMed
Smulders, K., Salaets, E., Houdt, M. V., Han, S., Punie, K., Wildiers, H. P. M. W., Regan, M. M., Brouckaert, O., & Neven, P. (2021) · European Journal of Gynaecological Oncology · doi:10.31083/j.ejgo4204097
Bright, E. E., Genung, S. R., Stanton, A. L., & Arch, J. J. (2021) · Research Square · doi:10.21203/rs.3.rs-974314/v1
Wako, Z., Mengistu, D., & Dinegde, N. G. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s353793
Bahri, M. H., Ariana, M., Khoshdel, A., & Naseri, A. (2022) · Journal of Archives in Military Medicine · doi:10.5812/jamm.120371
Introduction to Pharmaceutical Care and Medication Adherence
(2020) · Advances in medical technologies and clinical practice book series · doi:10.4018/978-1-7998-3832-6.ch001
Poorvu, P. D., & Partridge, A. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-24762-1_1
Psychiatric aspects of care in the cancer patient
BREITBART, W. S., Alici, Y., & Kurzrok, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821976-8.00026-8
HORMONIOTERAPIA E SEUS DESDOBRAMENTOS NO TRATAMENTO DO CÂNCER DE MAMA
Pinheiro, M. F. I. M., Aguiar, A. O., Valente, C. S. L., LEMES, L. D. A., Paiva, L. D., Karaja, L. I. H., QUEIROZ, L. F. D., Nascimento, M. A., Vieira, N. B. S., Fleury, R. M. G., et al. (2022) · Editora Pasteur eBooks · doi:10.29327/559580.4-14
Tamoxifen-related endocrine symptoms in Chinese patients with breast cancer
Chan, C. W. H. (2019) · http://isrctn.com/ · doi:10.1186/isrctn10773849
Sheppard, V. B., Namoos, A. M., Bonny, M., Arnethea, S., Edmonds, M. C., Bastaich, D., Cummings, Y., Wells, M., & Mendoza, A. D. (2022) · Research Square · doi:10.21203/rs.3.rs-1976539/v1
AlOmeir, O., Patel, N., & Donyai, P. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s368636
Kesztyüs, D., Kämpfer, J., & Kesztyüs, T. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192315486
Dowling, B., Forsyth, J. J., Zumwalt, M. A., & Robert-McComb, J. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-15485-0_4
Green, S. M. C., Hall, L., Rousseau, N., et al. (2023) · Research Open (London South Bank University) · doi:10.3310/nihropenres.14463.r29031
Green, S. M. C., Hall, L., Rousseau, N., et al. (2023) · NIHR Open Research · doi:10.3310/nihropenres.14463.r28987
Green, S. M. C., Hall, L., Rousseau, N., et al. (2023) · Research Open (London South Bank University) · doi:10.3310/nihropenres.14552.r29196
Green, S. M. C., Hall, L., Rousseau, N., et al. (2023) · NIHR Open Research · doi:10.3310/nihropenres.14552.r29195
PERÍCIA ODONTO LEGAL: O PROFISSIONAL DE ODONTOLOGIA COMO AUXILIAR DA JUSTIÇA NA SOLUÇÃO DE CRIMES
Silva, V. L. L. D., & Tavares, B. D. S. C. (2023) · Editora Enterprising eBooks · doi:10.29327/5238060.1-9
COSMÉTICA E BELEZA: A EVOLUÇÃO DA INDÚSTRIA DE FÁRMACOS
Baia, A. C. D. S., & Tavares, B. D. S. C. (2023) · Editora Enterprising eBooks · doi:10.29327/5238060.1-2
O AUMENTO DA AUTOMEDICAÇÃO DURANTE A PANDEMIA DO COVID-19
Pinheiro, E. V. D. S., & Tavares, B. D. S. C. (2023) · Editora Enterprising eBooks · doi:10.29327/5238060.1-5
SAÚDE MENTAL: AS AÇÕES DA ENFERMAGEM NO TRATAMENTO DE ADOLESCENTES USUÁRIOS DE DROGAS
Monteiro, V. G. D. S., & Tavares, B. D. S. C. (2023) · Editora Enterprising eBooks · doi:10.29327/5238060.1-3
Adjuvant antihormonal treatment in breast cancer. Understanding how poor adherence affects survivalPreprint
Dragvoll, I., Bofin, A. M., Søiland, H., Salvesen, Ø. O., & Engstrøm, M. J. (2023) · Research Square · doi:10.21203/rs.3.rs-3071927/v1
He, W., Zeng, E., Sjölander, A., Hűbbert, L., Hedayati, E., & Czene, K. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.23752
Tamoxifen besser verträglich durch überwachte Dosisreduktion
(2023) · Deutsche Zeitschrift für Onkologie · doi:10.1055/a-2182-8045
The experiences of adjuvant endocrine therapy for women breast cancer survivors: A literature review
Long, Y., Xie, S., Liu, Q., Xu, F., Li, Q., Wang, N., & Zhang, Y. (2023) · Medicine · doi:10.1097/md.0000000000036704
Terapia oral antineoplásica: análise da adesão e fatores associados
Bernardes, M. P. A. (2021) · doi:10.11606/d.7.2021.tde-12012022-171631
Kim, S. H., & Lee, J. (2024) · Archives of Women s Mental Health · doi:10.1007/s00737-024-01471-z
Green, S. M. C., & Smith, S. G. (2024) · NIHR Open Research · doi:10.3310/nihropenres.13547.1
Breast cancer risk reduction: Beyond pharmacologic intervention
Dent, S. F., Tumlinson, R., Guha, A., & Moore, H. (2024) · Cancer · doi:10.1002/cncr.35442
Indian Society of Medical and Paediatric Oncology (ISMPO)—Breast Cancer in Young Guidelines
Bajpai, J., Gandhi, S. S., Rajappa, S. J., Pathak, R. S., Joshi, S. P., Batra, A., Singh, M., Ghosh, J., Rangarajan, B., Prakash, G., et al. (2024) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0044-1785219
How to deal with the side effects of long-term pharmacotherapy with aromatase inhibitors?
Jagiełło-Gruszfeld, A. (2024) · Oncoreview · doi:10.24292/01.or.141301324
Optimierung der Versorgung durch digitale Anwendungen am Beispiel des Mammakarzinoms
Jansen, H., Dinkel, A., Benning, K., Hapfelmeier, A., Balteanu, A., Schüttig, W., Himmler, S., Fall, B., & Kiechle, M. B. (2024) · Die Gynäkologie · doi:10.1007/s00129-024-05296-w
Makhlin, I. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.47541
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5755-6
McPeek, C., Paul, S., Lieberenz, J. L., & Levy, M. A. (2024) · JCO Clinical Cancer Informatics · doi:10.1200/cci.24.00115
Uno, M., Takahashi, Y., Hatono, M., Kawada, K., Tsukioki, T., Kochi, M., Ikeda, H., Iwatani, T., Iwamoto, T., Hara, K., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5412576/v1
Turcotte, V., Guillaumie, L., Lemay, M., Dionne, A. R., Lemieux, J., Labbé, A., Gotay, C. C., Guénette, L., & Lauzier, S. (2025) · Current Oncology · doi:10.3390/curroncol32010045
On the Origin of Treatment Paradigms
McFarlane, M., Beeler, W. H., Ward, M. C., & Shah, C. (2025) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001181
Échanges autour des soins oncologiques
Sicard, J. (2025) · Actualités Pharmaceutiques · doi:10.1016/j.actpha.2025.01.012
Hormonal Treatment for Breast Carcinoma
Morey, K. H., Sabnis, J. M., Shinde, P. S., Shukla, R. K., Singh, S., Kolanu, N. D., & Kaulgud, V. (2025) · Journal of Datta Meghe Institute of Medical Sciences University · doi:10.4103/jdmimsu.jdmimsu_158_23
Long, L., Zhou, Z., Berg, W. A., Arefan, D., & Wu, S. (2025) · SPIE Medical Imaging: Imaging Informatics for Healthcare, Research, and Applications · doi:10.1117/12.3049128
Gedfew, M., Getie, ፟., Ayenew, T., & Amha, H. (2025) · Research Square · doi:10.21203/rs.3.rs-6582886/v1
Guerra, A. C. C. G., Matias, G. H. D. L., Filho, B. A. B. D. S., Tritany, É. F., Silva, V. L. C. F. D., do Carmo, C. N., Alves, J. G. B., Lima, J. T. D. O., & da Silva, J. R. (2025) · Fisioterapia e Pesquisa · doi:10.1590/1809-2950/e23004624en
Guerra, A. C. C. G., Matias, G. H. D. L., Filho, B. A. B. D. S., Tritany, É. F., Silva, V. L. C. F. D., do Carmo, C. N., Alves, J. G. B., Lima, J. T. D. O., & da Silva, J. R. (2025) · Fisioterapia e Pesquisa · doi:10.1590/1809-2950/e23004624pt
Budaycı, Ö., & Özkan, S. (2025) · Pamukkale Medical Journal · doi:10.31362/patd.1621040
Lapointe, J., Guillaumie, L., Dionne, A. R., Lalonde, L., Lemieux, J., Dorval, M., Nabi, H., Lemay, M., Guénette, L., Guertin, J. R., et al. (2025) · Pilot and Feasibility Studies · doi:10.1186/s40814-025-01676-8
Cuba, L., Dörje, F., Kramer, R., Dürr, P., Erdmann, M., Fromm, M. F., Berking, C., & Gessner, K. (2025) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15809
Cuba, L., Dörje, F., Kramer, R., Dürr, P., Erdmann, M., Fromm, M. F., Berking, C., & Gessner, K. (2025) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15809_g
Kalyani, G., Ma, C. X., Pruneda, P. S., Fatima, B., Sheriff, R., Abughosh, S., Ozuna, R., & Trivedi, M. V. (2025) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-025-02051-6
Multimodal Sensing and Modeling of Endocrine Therapy Adherence in Breast Cancer Survivors
Yuan, F., Kaur, N., Wang, Z., Gonzales, M., Alcaraz, C. G., Estrella, G., Wells, K. J., & Barnes, L. E. (2025) · Proceedings of the ACM on Interactive Mobile Wearable and Ubiquitous Technologies · doi:10.1145/3770864
Yeh, C., Chou, Y., Lin, S., Liu, C., & Huang, N. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09962-0
Foldi, J., Tsagianni, A., Salganik, M., Schnabel, C. A., Brufsky, A., Londen, G. J. V., Pusztai, L., & Sanft, T. B. (2023) · Figshare · doi:10.6084/m9.figshare.23612391
Foldi, J., Tsagianni, A., Salganik, M., Schnabel, C. A., Brufsky, A., Londen, G. J. V., Pusztai, L., & Sanft, T. B. (2023) · Figshare · doi:10.6084/m9.figshare.23612394
Foldi, J., Tsagianni, A., Salganik, M., Schnabel, C. A., Brufsky, A., Londen, G. J. V., Pusztai, L., & Sanft, T. (2023) · Figshare · doi:10.6084/m9.figshare.23612397
Artignan, J., Capmas, P., Panjo, H., Constantinou, P., & Pelletier‐Fleury, N. (2023) · Figshare · doi:10.6084/m9.figshare.24633241
Foldi, J., Tsagianni, A., Salganik, M., Schnabel, C. A., Brufsky, A., Londen, G. J. V., Pusztai, L., & Sanft, T. B. (2023) · Figshare · doi:10.6084/m9.figshare.23612388
Green, S. M. C., French, D., Graham, C. D., Hall, L., Rousseau, N., Foy, R., Clark, J., Parbutt, C., Raine, E., Gardner, B., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20619870
Green, S. M. C., French, D., Graham, C. D., Hall, L., Rousseau, N., Foy, R., Clark, J., Parbutt, C., Raine, E., Gardner, B., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20619867
Green, S. M. C., French, D., Graham, C. D., Hall, L., Rousseau, N., Foy, R., Clark, J., Parbutt, C., Raine, E., Gardner, B., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20619876
Differential Effectiveness of Aromatase Inhibitors in Hormone Receptor–Positive Breast Cancer
Pinheiro, L. C., & Rosenberg, S. M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.51548
Nebenwirkungsmanagement von Langzeittherapien beim frühen Mammakarzinom
Stefan, A., König, A., Bampi, A., Harbeck, N., & Würstlein, R. (2025) · Die Gynäkologie · doi:10.1007/s00129-025-05444-w
Extended aromatase inhibitor therapy for early breast cancer
Krishnan, A., & Mukherjee, D. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02358-x
Brandstetter, L., Grau, A., Müller-Reiter, M., Salmen, J., Müller-Nordhorn, J., Beck, N., Heuschmann, P., Störk, S., Wöckel, A., & Reese, J. (2026) · BMC Cancer · doi:10.1186/s12885-026-15641-y
Mokbel, K., Weedon, M. N., Moye, V., Ruth, K. S., & Jackson, L. M. (2026) · npj Breast Cancer · doi:10.1038/s41523-026-00923-2
Gut microbiome in integrative oncology
Lacey, J., Stringer, A. M., Cross, C., & Wardill, H. R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30194-0.00004-7
Meyer, H., Koppold, D. A., Shaker, O., Eden, L., Schiffmann, L., Konigorski, S., Cramer, H., Choi, K., Einsele, H., Winkler, M., et al. (2026) · Integrative Cancer Therapies · doi:10.1177/15347354261426272
Behandlung vasomotorischer Symptome bei Patientinnen mit Brustkrebs
Schäffler, H., Janni, W., & Pfister, K. (2026) · Gynäkologische Endokrinologie · doi:10.1007/s10304-026-00678-w
Belback, J., Zhou, Z., Long, L., Arefan, D., & Wu, S. (2026) · SPIE Medical Imaging: Computer-Aided Diagnosis · doi:10.1117/12.3088116
Martínez-Miranda, P., Muñoz-Fernández, M. J., Rosales‐Tristancho, A., & García‐Muñoz, C. (2026) · Healthcare · doi:10.3390/healthcare14091179
Setiawardani, M. F., Cholisoh, Z., & Hapsari, P. M. (2026) · JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA · doi:10.20473/jfiki.v13i12026.20-30
Ruggeri, S. Y., Lippincott, C. L. R., Alexander, G. L., Ellis, R. J. B., Chesnut, S. R., & Erickson, L. A. (2026) · Cancer Medicine · doi:10.1002/cam4.71925
Green, S. M. C., McNaught, E., Graham, C. D., Dowse, A., Wilkes, H., Ow, P. L., Travis, E., Foy, R., French, D., Hall, L., et al. (2026) · Trials · doi:10.1186/s13063-026-09765-6
Arrato, N. A., Monroe, A. D., Keefe, F. J., Kimmick, G. G., & Shelby, R. A. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1831434
Arch, J. J., Russell, S., Genung, S. R., Donahue, M. L., & Levin, M. E. (2026) · BMJ Connections Oncology · doi:10.1136/bmjconc-2025-000097
Stickland, A., Tao, X., Kidwell, K., & Henry, N. L. (2026) · Breast Cancer Research and Treatment · doi:10.1007/s10549-026-07977-7
Russo, R. G., Hernán, M. Á., Dahabreh, I. J., Rimm, E. B., Veiga, L. H. S., Hurson, A. N., Curtis, R. E., Pfeiffer, R. M., Booker, Q., Corley, M. E., et al. (2026) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djag158
Dibner-Dunlap, A., Sutermaster, S., Smittenaar, P., & Sgaier, S. K. (2026) · Research Square · doi:10.21203/rs.3.rs-9944098/v1
Campbell, T. M., Campbell, E. K., Blanchard, B. L. M., Wixom, N., Spath, K. M., & Peppone, L. J. (2026) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2026.109405
Gavin, K. L., Tiegs, J., Winn, A. N., Makris, V., Neuner, J. M., & Flynn, K. E. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-10915-4
Fong, J. S., Ling, T. P., Chow, M. T. N., Ong, W. S., Teo, I., Tan, R. S. Y. C., & Ramalingam, M. B. (2026) · JMIR Research Protocols · doi:10.2196/91330
Cortell-Aznar, S., Ruiz‐Robledillo, N., Ferrer‐Cascales, R., Fernández‐Alcántara, M., Albaladejo-Blázquez, N., & Delgado-García, S. (2026) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002849
Queiroz, A. P. M. O., de Aguiar, V. S., Borges, L. M., & dos Santos, J. R. B. (2026) · Psicologia e Saúde em Debate · doi:10.22289/2446-922x.v12a1a75
Haggstrom, L., Middleton, K., Parker, A., Segara, D., Ong, A., Bingham, J., Carson, E., Kiely, B. E., Sabanathan, D., Spillane, A. J., et al. (2026) · npj Breast Cancer · doi:10.1038/s41523-026-01008-w
Pinkerton, J. V., Simon, J. A., Panay, N., Nappi, R. E., Brennan, D. J., Donders, G. G. G., Soares, C. N., Maki, P. M., Caetano, C., Haberland, C., et al. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109075
Metadata
- Authors
- Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Murphy, Caitlin C.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2012-06-12
- Volume
- 134
- Issue
- 2
- Pages
- 459-478
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- PMC
- PMC3607286
- OpenAlex
- W1987753117
- Semantic Scholar
- 92816b1cff05e88d3955bfa52d7d9c9f3eafb040
- Cited by
- 708
- References
- 85
- Citations by year
- 2026: 32 · 2025: 63 · 2024: 59 · 2023: 67 · 2022: 71 · 2021: 59 · 2020: 60 · 2019: 54 · 2018: 41 · 2017: 64 · 2016: 33 · 2015: 38 · 2014: 32 · 2013: 34 · 2012: 1
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R25CA057712, R01CA112223, K07CA140159)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- adjuvant endocrine therapy, breast cancer survivors, medication adherence, treatment persistence, tamoxifen, aromatase inhibitors, hormone receptor-positive breast cancer, out-of-pocket costs, treatment side effects, behavioral interventions
- MeSH terms
- Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Neoplasms, Hormone-Dependent, Chemotherapy, Adjuvant, Survivors, Antineoplastic Agents, Hormonal, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
